close
close

topicnews · October 25, 2024

US Penny Stocks to Watch in October 2024

US Penny Stocks to Watch in October 2024

As the US stock market posts a mixed performance, with the S&P 500 and Nasdaq rising while the Dow continues its losing streak, investors are closely watching economic indicators for signs of stability. In this context, penny stocks – although an older term – remain relevant because they often represent smaller or newer companies with potential growth opportunities at lower prices. When supported by strong financial fundamentals, these stocks can offer compelling prospects without some of the typical risks associated with this investment category.

name

Share price

Market capitalization

Financial health assessment

BAB (OTCPK:BABB)

$0.7553

$5.71 million

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.15

$526.12 million

★★★★★★

RLX Technology (NYSE:RLX)

$1.60

$2.03 billion

★★★★★★

ARC Document Solutions (NYSE:ARC)

$3.43

$147.91 million

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.58

$53.13 million

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71 million

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$3.68

$112.23 million

★★★★★★

Better Choice (NYSEAM:BTTR)

$1.70

$2.96 million

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6 million

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.05

$96.23 million

★★★★★☆

Click here to see the full list of 760 stocks from our US Penny Stocks Screener.

We will examine a selection of our screener results.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Quince Therapeutics, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing therapies for debilitating and rare diseases with a market capitalization of $37.65 million.

Operations: Quince Therapeutics, Inc. did not report any revenue segments.

Market capitalization: $37.65 million

Quince Therapeutics is a pre-revenue biopharmaceutical company with a market capitalization of $37.65 million focused on developing therapies for rare diseases. Despite an elevated debt-to-equity ratio of 29.5% over five years, the company has more cash than total debt and has not significantly diluted shareholders recently. The management team is relatively new, with an average tenure of 1.4 years, while the board is experienced, with an average tenure of 5.6 years. Results from Quince’s Phase 3 ATTeST trial, recently published in The Lancet Neurology, showed promising safety data for its lead product EryDex, which has received Fast Track designation from the FDA for the treatment of ataxia-telangiectasia (AT).

NasdaqGS:QNCX Debt-to-Equity History and Analysis as of October 2024

Simply Wall St Financial Health Rating: ★★★★★☆